Drug: Tagrisso (Osimertinib) to Treat NSCLC
Osimertinib or Tagrisso is an FDA-approved drug by FDA as a frontline treatment for patients with non-small cell lung cancer (NSCLC). It is indicated for the first-line lung cancer treatment of patients with metastatic NSCLC whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 L858R mutations. It is used only when the tumor has a specific genetic marker. It is usually given after other cancer medicines have not been successfully. Working and Dosage People treated with Osimertinib usually develop resistance within 10 months. The resistance mediated by exon 20 C797S mutation accounts for majority of cases. It works by blocking the pathways that are responsible for the growth of tumor. So, this helps to stop the spread of tumor. The drug has shown significant improvement in comparison to chemotherapy. The recommended dosage of Osimertinib is 80 mg orally once daily, with or without food. Precautions to be taken Before taking Osimertinib, you should inform your